A Phase 2, Randomized, Active-Controlled, Observer-Blinded Trial, to Assess the Safety, Tolerability, and Immunogenicity of Gardasil (HPV) Vaccine and Bivalent rLP2086 Vaccine When Administered Concomitantly in Healthy Subjects Aged ≥ 11 to <18 Years

Trial Profile

A Phase 2, Randomized, Active-Controlled, Observer-Blinded Trial, to Assess the Safety, Tolerability, and Immunogenicity of Gardasil (HPV) Vaccine and Bivalent rLP2086 Vaccine When Administered Concomitantly in Healthy Subjects Aged ≥ 11 to <18 Years

Completed
Phase of Trial: Phase II

Latest Information Update: 30 May 2017

At a glance

  • Drugs PF 5212366 (Primary) ; Human papillomavirus vaccine recombinant quadrivalent Merck
  • Indications Human papillomavirus infections
  • Focus Adverse reactions; Pharmacodynamics
  • Sponsors Pfizer
  • Most Recent Events

    • 30 May 2017 According to a Pfizer media release, the European Commission (EC) has approved TRUMENBA (Meningococcal Group B Vaccine) for the prevention of invasive meningococcal disease caused by Neisseria meningitidis serogroup B (MenB) in individuals 10 years of age and older. Results from this study supported the approval.
    • 01 Feb 2016 Results published in the Pediatric Infectious Disease Journal.
    • 01 Jul 2013 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top